Cargando…
Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors
OBJECTIVES: To assess the efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis (RA) and poor prognostic factors. METHODS: In this double-blind, phase IIIb study, patients with RA for 2 years or less were randomly assigned 1 : 1 to receive abatacept (∼10 mg/...
Autores principales: | Westhovens, R, Robles, M, Ximenes, A C, Nayiager, S, Wollenhaupt, J, Durez, P, Gomez-Reino, J, Grassi, W, Haraoui, B, Shergy, W, Park, S-H, Genant, H, Peterfy, C, Becker, J-C, Covucci, A, Helfrick, R, Bathon, J |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BMJ Group
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2770104/ https://www.ncbi.nlm.nih.gov/pubmed/19124524 http://dx.doi.org/10.1136/ard.2008.101121 |
Ejemplares similares
-
Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosis
por: Westhovens, Rene, et al.
Publicado: (2015) -
Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE)
por: Smolen, Josef S., et al.
Publicado: (2015) -
Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial)
por: Emery, P, et al.
Publicado: (2009) -
Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial
por: Genant, H K, et al.
Publicado: (2008) -
Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial
por: Kremer, Joel M, et al.
Publicado: (2011)